1,578 reports of this reaction
3.2% of all HALOPERIDOL reports
#3 most reported adverse reaction
NEUROLEPTIC MALIGNANT SYNDROME is the #3 most commonly reported adverse reaction for HALOPERIDOL, manufactured by Advagen Pharma Ltd. There are 1,578 FDA adverse event reports linking HALOPERIDOL to NEUROLEPTIC MALIGNANT SYNDROME. This represents approximately 3.2% of all 49,192 adverse event reports for this drug.
Patients taking HALOPERIDOL who experience neuroleptic malignant syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROLEPTIC MALIGNANT SYNDROME is moderately reported among HALOPERIDOL users, representing a notable but not dominant share of adverse events.
In addition to neuroleptic malignant syndrome, the following adverse reactions have been reported for HALOPERIDOL:
The following drugs have also been linked to neuroleptic malignant syndrome in FDA adverse event reports:
NEUROLEPTIC MALIGNANT SYNDROME has been reported as an adverse event in 1,578 FDA reports for HALOPERIDOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROLEPTIC MALIGNANT SYNDROME accounts for approximately 3.2% of all adverse event reports for HALOPERIDOL, making it one of the most commonly reported side effect.
If you experience neuroleptic malignant syndrome while taking HALOPERIDOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.